Alzheimer Disease Clinical Trials in Miami, Florida

15 studies are recruiting for alzheimer disease in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Nuovida Research Center, Miami, Florida

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Hope Research Network - Miami, Miami, Florida

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

3. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0022, Miami, Florida

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

4. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   Allied Biomedical Research Institute (ABRI), Inc, Miami, Florida

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

5. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

   The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

   Stage

   Phase 4

   Ages

   50 and older

   Site

   CCM Clinical Research Group, LLC, Miami, Florida

   Locations

   14 in total

   Run by

   Alpha Cognition, Inc

   See if you can join NCT07633470 on ClinicalTrials.gov

6. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1159, Miami, Florida

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

7. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Finlay Medical Research, Miami, Florida

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

8. Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

   The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   University of Miami Department of Neurology, Miami, Florida

   Run by

   Bernard (Barry) Baumel

   See if you can join NCT06781333 on ClinicalTrials.gov

9. [18F]PI-2620 Phase 3 Histopathological Study

   This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

   Stage

   Phase 3

   Ages

   50 and older

   Site

   Miami Jewish Health Systems, Miami, Florida

   Locations

   25 in total

   Run by

   Lantheus Biosciences Ltd.

   See if you can join NCT05641688 on ClinicalTrials.gov

10. Clinical Trial on Agitation in Alzheimer's Dementia

    The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

    Stage

    Phase 2

    Ages

    60 and older

    Site

    Central Miami Medical Institute, Miami, Florida

    Locations

    31 in total

    Run by

    IGC Pharma, LLC

    See if you can join NCT05543681 on ClinicalTrials.gov

11. Late Onset Alzheimer's Disease

    The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to…

    Stage

    Not phased

    Ages

    55 and older

    Site

    University of Miami, Miami, Florida

    Locations

    12 in total

    Run by

    Columbia University

    See if you can join NCT05010603 on ClinicalTrials.gov

12. Combating Alzheimer's Through Sleep and Exercise

    The purpose of this research is to see how sleep and exercise affects dementia risk over time.

    Stage

    Not phased

    Ages

    45 to 80

    Site

    University of Miami Hospitals, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT04855630 on ClinicalTrials.gov

13. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

    The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

    Stage

    Not phased

    Ages

    50 to 85

    Site

    Baptist Health South Florida & Florida International University, Miami, Florida

    Locations

    10 in total

    Run by

    InSightec

    See if you can join NCT03671889 on ClinicalTrials.gov

14. Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

    Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per sec…

    Stage

    Not phased

    Ages

    50 and older

    Site

    Andrey Vyshedskiy, Miami, Florida

    Run by

    Alzheimer's Light LLC

    See if you can join NCT03657745 on ClinicalTrials.gov

15. Longitudinal Cognitive Assessment by BoCA

    The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis t…

    Stage

    Not phased

    Ages

    50 and older

    Site

    Andrey Vyshedskiy, Miami, Florida

    Run by

    Alzheimer's Light LLC

    See if you can join NCT04114994 on ClinicalTrials.gov